S4.4.4.2-4. McGill HC Jr, McMahan CA, Malcom GT, et al. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 1997;17:95 106. CLINICAL STATEMENTS AND GUIDELINES S4.4.4.2-5. Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipid- emia. Am J Cardiol. 2012;110:823 5. S4.4.4.2-6. Lloyd-Jones DM, Wilson PW, Larson MG, et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med. 2003;163:1966 72. S4.4.4.2-7. Domanski M, Lloyd-Jones D, Fuster V, et al. Can we dramatically reduce the incidence of coronary heart disease? Nat Rev Cardiol. 2011;8:721 5. S4.4.4.2-8. Durrington PN, Soran H. Cholesterol levels should play a more important role in identifying statin recipients. Circulation. 2017;135:627 9. S4.4.4.2-9. Thanassoulis G, Pencina MJ, Sniderman AD. The benefit model for prevention of cardiovascular disease: an opportunity to har- monize guidelines. JAMA Cardiol. 2017;2:1175 6. S4.4.4.2-10. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular dis- ease. N Engl J Med. 2012;366:321 9. S4.4.4.2-11. Lehr AL, Driver SL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505 6. S4.4.4.2-12. Omura JD, Watson KB, Loustalot F, et al. Primary care providers awareness of physical activity-related intensive behavioral coun- seling services for cardiovascular disease prevention. Am J Health Promot. 2018. 890117118784226. S4.4.4.2-13. Domanski MJ, Fuster V, Diaz-Mitoma F, et al. Next steps in primary prevention of coronary heart disease: rationale for and design of the ECAD trial. J Am Coll Cardiol. 2015;66:1828 36. S4.4.4.2-14. Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391 9. 4.4.4.3. Children and Adolescents S4.4.4.3-1. 